These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21280127)

  • 1. Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.
    Thompson LC; Goswami S; Ginsberg DS; Day DE; Verhamme IM; Peterson CB
    Protein Sci; 2011 Feb; 20(2):353-65. PubMed ID: 21280127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.
    Thompson LC; Goswami S; Peterson CB
    Protein Sci; 2011 Feb; 20(2):366-78. PubMed ID: 21280128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.
    Bucci JC; Trelle MB; McClintock CS; Qureshi T; Jørgensen TJ; Peterson CB
    Biochemistry; 2016 Aug; 55(31):4386-98. PubMed ID: 27416303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolving distinct molecular origins for copper effects on PAI-1.
    Bucci JC; McClintock CS; Chu Y; Ware GL; McConnell KD; Emerson JP; Peterson CB
    J Biol Inorg Chem; 2017 Oct; 22(7):1123-1135. PubMed ID: 28913669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin.
    Trelle MB; Hirschberg D; Jansson A; Ploug M; Roepstorff P; Andreasen PA; Jørgensen TJ
    Biochemistry; 2012 Oct; 51(41):8256-66. PubMed ID: 22957734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides.
    Germer M; Kanse SM; Kirkegaard T; Kjøller L; Felding-Habermann B; Goodman S; Preissner KT
    Eur J Biochem; 1998 May; 253(3):669-74. PubMed ID: 9654064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
    Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
    J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.
    Schar CR; Jensen JK; Christensen A; Blouse GE; Andreasen PA; Peterson CB
    J Biol Chem; 2008 Oct; 283(42):28487-96. PubMed ID: 18658131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
    Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
    J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
    Ngo TH; Hoylaerts MF; Knockaert I; Brouwers E; Declerck PJ
    J Biol Chem; 2001 Jul; 276(28):26243-8. PubMed ID: 11342530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting molecular details and functional effects of the high-affinity copper binding site in plasminogen activator Inhibitor-1.
    Chu Y; Bucci JC; Peterson CB
    Protein Sci; 2021 Mar; 30(3):597-612. PubMed ID: 33345392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.
    Blouse GE; Dupont DM; Schar CR; Jensen JK; Minor KH; Anagli JY; Gårdsvoll H; Ploug M; Peterson CB; Andreasen PA
    Biochemistry; 2009 Mar; 48(8):1723-35. PubMed ID: 19193026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix.
    Minor KH; Peterson CB
    J Biol Chem; 2002 Mar; 277(12):10337-45. PubMed ID: 11796716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis.
    Lawrence DA; Palaniappan S; Stefansson S; Olson ST; Francis-Chmura AM; Shore JD; Ginsburg D
    J Biol Chem; 1997 Mar; 272(12):7676-80. PubMed ID: 9065424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.
    Podor TJ; Shaughnessy SG; Blackburn MN; Peterson CB
    J Biol Chem; 2000 Aug; 275(33):25402-10. PubMed ID: 10821827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
    Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
    Sui GC; Wiman B
    Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.